<article id="efficacy_DME_response" class="slide tabbed" data-ag-name="Efficacy DME Response">
  <div class="tab-title">DME</div>

  <h2 class="slide-title">DEMONSTRATED REDUCTION <br>IN CENTRAL RETINAL THICKNESS<sup class="footnote-link">1,3‡</sup></h2>
    <div class="tabs">
      <ul>
        <li class="first" id="dme-response-active"><img src="content/img/vista-dme-bg.png" /></li>
        <li class="last"><img src="content/img/vivid-dme-bg.png" /></li>
      </ul>
    </div>
    <div class="chart" id="dme-response-first">
  
      <div class="chart-desc">
         Mean change in central retinal thickness from baseline at Week 52 (2<sup class="footnote-link">o</sup> endpoint)<sup class="footnote-link">‡</sup>
      </div>
  <div class="chart-img"><img src="content_EN/img/charts_cr-dme.png" /></div>
      <div class="chart-details">
        <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span>
      </div>
    </div>
    <div class="chart"  id="dme-response-last" style="display: none;">
  
      <div class="chart-desc">
         Mean change in central retinal thickness from baseline at Week 52 (2<sup class="footnote-link">o</sup> endpoint)<sup class="footnote-link">‡</sup>
      </div>
  <div class="chart-img"><img src="content_EN/img/charts_cr2-dme.png" /></div>
      <div class="chart-details">
        <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span>
      </div>
    </div>
  </div>
  <div class="keys">
    <div class="chart-key">‡ Clinical relevance unknown.</div>
    </div>
  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>A randomized, multicentre, double-blind, active-controlled study in adult patients with type 1 or type 2 diabetes presenting with central DME involvement in the study eye. Patients were assigned randomly in a 1:1:1 ratio to receive either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=155), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 5 initial monthly doses (n=154) or active control laser (n=156). Beginning at Week 24, patients meeting a<br>pre-specified threshold of vision loss were eligible to receive additional treatment: patients in EYLEA<sup class="reg">&reg;</sup> groups could receive laser and patients in laser group could receive EYLEA<sup class="reg">&reg;</sup>. EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 is not a recommended dose.
    </p>
    <p>
      <span class='bullet'>†</span>A randomized, multicentre, double-blind, active-controlled study in adult patients with type 1 or type 2 diabetes presenting with central DME involvement in the study eye. Patients were assigned randomly in a 1:1:1 ratio to receive either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=136), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 5 initial monthly doses (n=135) or active control laser (n=135). Beginning at Week 24, patients meeting a<br>pre-specified threshold of vision loss were eligible to receive additional treatment: patients in EYLEA<sup class="reg">&reg;</sup> groups could receive laser and patients in laser group could receive EYLEA<sup class="reg">&reg;</sup>. EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 is not a recommended dose.
    </p>
  </div>
</article>